Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.60 |
| ▸ | TYR | P14679 | 1/20 | 0.53 |
| ▸ | ERN1 | O75460 | 9/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
| ▸ | PELI1 | Q96FA3 | 1/20 | 0.42 |
| ▸ | IAPP | P10997 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13469126 | 1.00 | CNR2 (0.60) | CNR2TYRERN1KDM4EPTGS2 | |
| SCHEMBL6557065 | 0.86 | CNR2 (0.67) | CNR2TYRKDM4ERAB9ALCK | |
| SCHEMBL14205615 | 0.85 | CNR2 (0.55) | CNR2TYRKDM4EPTGS2RAB9A | |
| SCHEMBL3450955 | 0.84 | ERN1 (0.53) | ERN1KDM4EPTGS2RAB9ACDK1 | |
| SCHEMBL14281152 | 0.82 | ERN1 (0.52) | ERN1KDM4EPTGS2RAB9ACDK1 | |
| SCHEMBL21428814 | 0.81 | PTGS1 (0.50) | ERN1PTGS2LCKPTGS1 | |
| SCHEMBL1527062 | 0.81 | KDM4E (0.67) | ERN1KDM4EPTGS2RAB9ACDK1 | |
| SCHEMBL5470013 | 0.79 | PTPN1 (0.59) | ERN1LCKTRIM24TRIM33 | |
| SCHEMBL5470008 | 0.79 | PTPN1 (0.59) | ERN1LCKTRIM24TRIM33 | |
| Formic Acid SCHEMBL29030376 | 0.78 | CNR2 (0.62) | CNR2TYRKDM4EPTGS2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115487109-B | Bead-explosion fragrant pill with helicobacter pylori inhibiting function and preparation method thereof | 上海利康精准医疗技术有限公司 | 2024-02-27 | — | — | CN | claimed |
| CN-115487109-A | Bead-blasting chewing gum pill with function of inhibiting helicobacter pylori and preparation method thereof | 上海利康精准医疗技术有限公司 | 2022-12-20 | — | — | CN | claimed |
| US-20070014739-A1 | Compositions and methods for controlling biofilms and bacterial infections | SEQUOIA SCIENCES, INC. | 2007-01-18 | — | — | US | claimed |
| WO-2006019881-A2 | COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS AND BACTERIAL INFECTIONS | ELDRIDGE GARY R (US) | 2006-02-23 | — | — | WO | claimed |
| CN-115487109-B | Bead-explosion fragrant pill with helicobacter pylori inhibiting function and preparation method thereof | 上海利康精准医疗技术有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-115487109-A | Bead-blasting chewing gum pill with function of inhibiting helicobacter pylori and preparation method thereof | 上海利康精准医疗技术有限公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-114656515-A | Preparation method of loquat leaf triterpenic acid extract | 上海利康精准医疗技术有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-20220133634-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20210052503-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | AXIAL THERAPEUTICS, INC. (US) | 2021-02-25 | — | — | US | disclosed |
| US-20170263385-A1 | HYDROPHILIC CONJUGATED POLYMERS, AND METHODS OF PREPARATION AND USE THEREOF | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2017-09-14 | — | — | US | disclosed |
| US-7612045-B2 | Compounds, compositions and methods for controlling biofilms and bacterial infections | SEQUOIA SCIENCES, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080145322-A1 | Componds, Composition and Method for Controlling Biofolms and Bacterail Infections | SEQUOIA SCIENCES, INC. | 2008-06-19 | — | — | US | disclosed |
| EP-1797108-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS AND BACTERIAL INFECTIONS | Eldridge, Gary R. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20070014739-A1 | Compositions and methods for controlling biofilms and bacterial infections | SEQUOIA SCIENCES, INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2006031943-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS AND BACTERIAL INFECTIONS | ELDRIDGE GARY R (US) | 2006-03-23 | — | — | WO | disclosed |
| WO-2006019881-A2 | COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS AND BACTERIAL INFECTIONS | ELDRIDGE GARY R (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052503-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | APC, SNCA, PARK7 | CNR2 3490/4885TYR 1610/4885ERN1 4794/4885 |
| US-20080145322-A1 | Componds, Composition and Method for Controlling Biofolms and Bacterail Infections | CFD, SBDS, F2 | CNR2 616/4885TYR 3994/4885ERN1 3561/4885 |
| US-20220133634-A1 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME | APC, SNCA, PARK7 | CNR2 3490/4885TYR 1610/4885ERN1 4794/4885 |
| US-20070014739-A1 | Compositions and methods for controlling biofilms and bacterial infections | RHOA, ALOX5, BLVRB | CNR2 2037/4885TYR 3680/4885ERN1 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.